K

    KALV (KALV)

    Official site

    BIOTECHNOLOGY

    $27.00
    +0.00 (+0.00%)

    Last updated: Jun 12, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(20/37)
    Avg Surprise
    +3.21%

    Upcoming Estimates

    Period ending Mar 31, 2026
    EPS Consensus$-0.38
    Range$-0.60 - $-0.06
    8 analysts
    EPS RevisionsNo revisions (7d)
    4
    2
    30d
    EPS Estimate Drift
    90d ago$-0.48-27.9%
    60d ago$-0.48-28.2%
    30d ago$-0.41-9.8%
    7d ago$-0.35+8.1%
    Current$-0.38
    Revenue Consensus
    $39M
    Range$33M - $45M
    8 analysts
    Period ending Jun 30, 2026
    EPS Consensus$-0.29
    Range$-0.43 - $-0.02
    6 analysts
    EPS RevisionsNo revisions (7d)
    4
    2
    30d
    EPS Estimate Drift
    90d ago$-0.38-32.1%
    60d ago$-0.30-3.5%
    30d ago$-0.26+9.3%
    7d ago$-0.26+9.3%
    Current$-0.29
    Revenue Consensus
    $49M
    Range$42M - $55M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.90---
    Sep 26EST
    		-$-0.27---
    Jun 26EST
    		-$-0.29---
    Mar 26EST
    		-$-0.38---
    Apr 26
    Reported May 15
    		$-0.43$-0.38-14.27%Miss+56.6%
    Jan 26
    Reported Mar 24
    		$0.94$-0.53+277.36%Beat+202.2%
    Oct 25
    Reported Nov 10
    		$-0.92$-0.91-1.10%Miss-1.1%
    Jul 25
    Reported Sep 11
    		$-1.12$-0.90-24.44%Miss-28.7%
    Apr 25
    Reported Jul 10
    		$-0.99$-0.81-22.22%Miss+2.9%
    Jan 25
    Reported Mar 12
    		$-0.92$-0.87-5.75%Miss-9.5%
    Oct 24
    Reported Dec 5
    		$-0.91$-0.91+0.00%Beat-13.7%
    Jul 24
    Reported Sep 5
    		$-0.87$-0.94+7.45%Beat-17.6%
    Apr 24
    Reported Jul 11
    		$-1.02$-0.73-39.73%Miss-32.5%
    Jan 24
    Reported Mar 11
    		$-0.84$-0.80-5.00%Miss-12.0%
    Oct 23
    Reported Dec 7
    		$-0.80$-0.78-2.56%Miss+11.1%
    Jul 23
    Reported Sep 7
    		$-0.74$-0.84+11.90%Beat+21.3%
    Apr 23
    Reported Jul 7
    		$-0.77$-0.94+18.09%Beat+21.4%
    Jan 23
    Reported Mar 9
    		$-0.75$-1.00+25.00%Beat+18.5%
    Oct 22
    Reported Dec 8
    		$-0.90$-1.05+14.29%Beat-12.5%
    Jul 22
    Reported Sep 8
    		$-0.94$-0.97+3.09%Beat-42.4%
    Apr 22
    Reported Jul 7
    		$-0.98$-1.09+10.09%Beat-46.3%
    Jan 22
    Reported Mar 10
    		$-0.92$-0.90-2.22%Miss-64.3%
    Oct 21
    Reported Dec 9
    		$-0.80$-0.75-6.67%Miss-37.9%
    Jul 21
    Reported Sep 9
    		$-0.66$-0.71+7.04%Beat-8.2%
    Apr 21
    Reported Jul 13
    		$-0.67$-0.54-24.07%Miss-81.1%
    Jan 21
    Reported Mar 11
    		$-0.56$-0.59+5.08%Beat-7.7%
    Oct 20
    Reported Dec 10
    		$-0.58$-0.66+12.12%Beat-75.8%
    Jul 20
    Reported Sep 14
    		$-0.61$-0.55-10.91%Miss-45.2%
    Apr 20
    Reported Jul 1
    		$-0.37$-0.61+39.34%Beat+24.5%
    Jan 20
    Reported Mar 10
    		$-0.52$-0.52+0.00%Beat-126.1%
    Oct 19
    Reported Dec 3
    		$-0.33$-0.54+38.89%Beat-50.0%
    Jul 19
    Reported Sep 9
    		$-0.42$-0.58+27.59%Beat+10.6%
    Apr 19
    Reported Jul 15
    		$-0.49$-0.42-16.67%Miss-716.7%
    Jan 19
    Reported Mar 14
    		$-0.23$-0.46+50.00%Beat+53.1%
    Oct 18
    Reported Dec 14
    		$-0.22$-0.42+47.62%Beat+56.0%
    Jul 18
    Reported Sep 14
    		$-0.47$-0.33-42.42%Miss+7.8%
    Apr 18
    Reported Jul 30
    		$-0.06N/A+82.86%Beat+86.4%
    Jan 18
    Reported Mar 16
    		$-0.49$-0.13-276.92%Miss+51.0%
    Oct 17
    Reported Dec 14
    		$-0.50$-0.45-11.11%Miss+60.3%
    Jul 17
    Reported Sep 14
    		$-0.51$-0.59+13.56%Beat-
    Apr 17
    Reported Jul 27
    		$-0.44N/AN/ABeat-
    Jan 17
    Reported Mar 16
    		$-1.00$-0.60-66.67%Miss-
    Oct 16
    Reported Nov 8
    		$-1.26N/AN/ABeat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$26.97
    SMA 20$26.88
    SMA 50$24.29
    SMA 200$16.98
    EMA 10$26.95
    EMA 20$26.60
    EMA 50$24.46
    EMA 200$18.55

    MACD

    Line: 0.68Signal: 0.90Hist: -0.21

    ADX

    ADX: 57.6+DI: 40.5-DI: 9.2

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down12.0
    PSAR$26.06

    Bollinger Bands

    Upper Band$27.08
    Lower Band$26.68
    %B Position148%(Upper)
    Band Width0.80

    RSI (14-Day)

    Overbought
    75.9

    Momentum Oscillators

    Stoch %K100.0
    Stoch %D99.5
    Williams %RN/A
    ROC (10d)0.5%
    Momentum0.13
    CCI (20d)87.8
    MFI (14d)80.0

    Volatility Measures

    ATR (14d)$0.20(0.7%)
    StdDev (20d)0.10
    Hist Vol1.9%(Low)

    Volume Flow

    VWAP$27.00
    OBV113.7M
    AD Line-58.2M
    CMF (20d)0.039

    Volume Metrics

    Avg Vol (20d)3.1M
    Vol RatioN/A
    VWMA (20d)$26.84

    Pivot Points

    R3$27.00
    R2$27.00
    R1$27.00
    Pivot Point$27.00
    S1$27.00
    S2$27.00
    S3$27.00

    Advanced Oscillators

    TSI51.12
    Ultimate Osc65.4
    KST131.07

    Financial Data

    QuarterApr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023Jul 2023
    Total Revenue$59.92M$40.86M$40.86M$1.43M$0$0$0$0$1.21M$0$0$0
    Cost of Revenue$3.98M$3.09M$3.44M$590,000$15.89MN/AN/A$224,000$25.25M$207,000$19.09M$19.31M
    Gross Profit$55.95M$37.77M$37.42M$836,000$-15,891,000N/AN/A$-224,000$-25,248,000$-207,000$-19,089,000$-19,307,000
    Operating Expenses$67.46M$64.31M$60.86M$59.84M$39.14M$42.94M$45.81M$44.22M$23.21M$32.94M$10.66M$9.79M
    R&D$8.85M$12.42M$12.42M$15.16M$15.89M$12.59M$16.61M$26.61M$25.25M$22.52M$19.09M$19.31M
    SG&A$0$48.80M$46.52M$44.68M$39.14M$30.35M$29.20M$17.60M$23.21M$10.63M$10.66M$9.79M
    Operating Income$-11,511,500$-23,442,000$-23,442,000$-59,009,000$-55,030,000$-42,940,000$-45,811,000$-44,215,000$-48,455,000$-33,151,000$-29,746,000$-29,093,000
    Interest Income$0$2.55M$0$1.85M$1.99M$1.39M$1.36M$1.69M$1.51M$684,000$776,000$923,000
    Interest Expense$8.65M$5.59M$5.59M$3.52M$2.94M$2.84M$0$0$0$0$0$0
    Income Before Tax$-12,470,500$-23,487,000$-23,487,000$-57,939,000$-53,081,000$-44,262,000$-42,268,000$-40,443,000$-44,649,000$-29,028,000$-27,650,000$-25,317,000
    Income Tax Expense$-7,098,500$0$2.16M$2.16M$-855,000$4.25M$0$0$856,000$0$523,000$-1,379,000
    Net Income$-5,372,000$-23,487,000$-23,487,000$-60,096,000$-52,226,000$-48,509,000$-42,268,000$-40,443,000$-44,649,000$-29,028,000$-27,650,000$-25,317,000
    EBITDA$-3,236,500N/A$-17,546,000$-54,165,000$-49,877,000$-41,191,000$-42,041,000$-40,219,000$-44,430,000$-28,821,000$-27,453,000$-25,124,000
    EBIT$-3,823,000N/A$-17,901,000$-54,417,000$-50,138,000$-41,420,000$-42,268,000$-40,443,000$-44,649,000$-29,028,000$-27,650,000$-25,317,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KALV

    News

    KalVista Pharmaceuticals (KALV): Venrock group now reports 0% ownership stake

    Venrock-affiliated entities and individuals, including Nimish Shah and Bong Y. Koh, have filed an amended Schedule 13G/A for KalVista Pharmaceuticals (KALV), reporting a 0% beneficial ownership stake as of June 30, 2026. This indicates they no longer hold any shares or have voting/dispositive power over KalVista common stock. The filing confirms that the group owns less than 5% of the common stock and is a passive investor.

    Stock Titan•8/14/26•
    Neutral

    Tang Capital exits KalVista Pharmaceuticals (KALV) reporting 0% beneficial ownership

    Tang Capital entities, including Tang Capital Management, LLC and Kevin Tang, have filed an amended Schedule 13G/A, declaring 0% beneficial ownership in KalVista Pharmaceuticals (KALV). This filing indicates that Tang Capital now holds no shares of KalVista common stock, marking a complete exit from their previous investment. The disclosure details 0 shares for voting and dispositive power, confirming their ownership has dropped below the 5% threshold for passive investors.

    Stock Titan•8/14/26•
    Somewhat-Bearish

    KalVista Pharmaceuticals (KALV) investor SilverArc now reports 0% ownership stake

    SilverArc Capital Management, LLC and Devesh Gandhi have filed an amended Schedule 13G/A, disclosing that they no longer beneficially own any shares of KalVista Pharmaceuticals, Inc. (KALV). They now report 0 shares, representing a 0% ownership stake in the company's Class A Common Stock, with no voting or dispositive power. This filing indicates they are owners of 5 percent or less of this class of securities.

    Stock Titan•8/14/26•
    Neutral

    KalVista Pharmaceuticals (NASDAQ: KALV) investor reports 0% ownership in Class A stock

    SilverArc Capital Management, LLC and Devesh Gandhi have reported a 0% beneficial ownership in KalVista Pharmaceuticals, Inc.'s Class A Common Stock, holding 0 shares with no voting or dispositive power. This Schedule 13G filing indicates that their ownership now falls below 5% of the class. The disclosure provides details on the reporting persons and the specific Class A Common Stock security (CUSIP 483497AA1) to which the filing pertains.

    Stock Titan•8/11/26•
    Neutral

    Pharvaris moves closer to bringing second oral on-demand HAE therapy to US

    Pharvaris is advancing its efforts to introduce a second oral on-demand therapy for Hereditary Angioedema (HAE) in the US. This move signals potential new treatment options for patients. The article focuses on the company's progress and the implications for the HAE market.

    FirstWord Pharma•7/6/26•
    Bullish

    Frequently Asked Questions About KALV

    Does KALV pay dividends?
    KALV (KALV) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In